Overview

Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine how the organism affects MMF (metabolite of dimethyl fumarate [DMF]) after single oral dose administration of LAS41008 120 mg gastroresistant tablet and Fumaderm® 120 mg gastro-resistant tablet under fasting and fed conditions. The study also aims to assess the safety of the study treatments.
Phase:
Phase 1
Details
Lead Sponsor:
Almirall, S.A.
Treatments:
Dimethyl Fumarate